Cancer Immunotherapy Program Research Scientist Leslie Cousens, PhD receives $10,000 Rhode Island Research Foundation grant to conduct preclinical studies to optimize culture conditions for ex vivo expansion of immune effector cells.
Cancer Immunotherapy Program opens enrollment for phase I clinical trial to test safety of investigational new drug in patients with advanced Non-Small Cell Lung Cancers.
Cancer Immunotherapy Program receives $600,000 grant award from the FDA Orphan Drug Development Program and NCI for phase I clinical trial to test safety of investigational drug in advanced Non-Small Cell Lung Cancer patients.
Cancer Immunotherapy Program Investigational New Drug application (BB-IND 13282) for anti-CD3 x cetuximab bispecific antibody-armed activated T cells cleared by FDA to begin phase I testing.
Home
| About
Us | News
| Research
| Contact
Us
Directory | Physician
Finder
Patient Care Information |
Employment Opportunities
Ways of Giving
| Content
for Physicians
|